Find a Clinical Trial

Showing 1 - 10 of 28 Trials

  • A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer

    Principal Investigator:

    Yoanna S Pumpalova, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05379595

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to see if the study drug,amivantamab (also known as Rybrevant TM) is safe and useful for treating patients with Colorectal Cancer (CRC) when it is given alone or in addition to standard-of-care chemotherapies (mFOLFOX6 or FOLFIRI), as well as to find the best dose of amivantamab when given with chemotherapies. Amivantamab is an antibody made from a protein, designed to target and eliminate a specific harmful object in your body, in this case, a cancer cell. Amivantamab works by targeting a protein in your body known as epidermal growth factor receptor (EGFR), that...

  • A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    Principal Investigator:

    Yoanna S Pumpalova, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06662786

    Population:

    Adult

    Phase:

    III
    The purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapies to participants with metastatic (cancerous) CRC that lack mutations in genes called KRAS/NRAS and BRAF. Amivantamab is an investigational drug in this study, meaning it is currently being tested and has not been approved by the United States Food and Drug Administration (FDA) for your disease. This is why amivantamab is being compared with cetuximab, an FDA-approved treatment, to evaluate its efficacy and...

  • Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma

    Principal Investigator:

    Lisa Ann Kachnic, MD, FASTRO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05838391

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to find out if performing adaptive planning during the treatment anal cancer will decrease the dose of radiation to normal organs and decrease the side effects. In this study, subjects will have a daily adjustment (adaptation) of their radiation plan as the tumor changes during the radiation treatment. The radiation will be given as part the standard of care treatment with chemotherapy, known as chemo-RT (CRT). Are you Eligible? (Inclusion Criteria) To be considered for this study, you must: 1. Have invasive anal cancer confirmed with biopsy 2. Be greater than 18...

  • A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

    Principal Investigator:

    Gulam A. Manji, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06445062

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to test the safety of an experimental drug called RMC-6236 in combination with several chemotherapy medicines in patients with gastrointestinal cancers. The study will test the safety of RMC-6236 at different doses in combination with a fixed, standard dose of combination anti-cancer therapy, and how your body processes this combination. RMC-6236 is an investigational (experimental) drug, which means that it has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older -...

  • A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06625775

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR- positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer (aCRC) with a KRAS mutation.BBO-10203 has not been approved by the Food and Drug Administration (FDA). Trastuzumab is FDA approved but not in combination with BBO-10203. This is a first in human study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older...

  • An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04794699

    Population:

    Adult

    Phase:

    I
    IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not “on the market” (available for you to receive a prescription for and/or to buy) in any country. In this study, different dose levels of IDE397 will be tested. About 40 patients are expected to participate at approximately 6-8 study centers within the US. At a minimum, 2 patients will be enrolled in each dose level. There will be about 10 dose levels tested (starting at 5 mg). Every time a dose level is found to be safe, a...

  • An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06561685

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...

  • A Phase 1 Open-Label Study of PF-07985045 as a Single-Agent and in Combination with Other Anti-Cancer Agents in Participants with Advanced Solid Tumors

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06704724

    Population:

    Adult

    Phase:

    I
    The purposes of this research study are (1) to learn about the safety and the effects of study drug, PF-07985045 on your specific cancer and on your body, with or without combination drugs and (2) to find the best dose for treating your specific type of cancer, as well as treating other types of cancers. This study is divided in two parts: Part 1 and Part 2. Part 1 testing and results applies to the study drug alone, called monotherapy. The goal of Part 1 is to determine the maximum tolerated dose (highest dose that is safe and tolerable in study participants, called MTDM and the recommended...

  • A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant SolidTumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06607185

    Population:

    Adult

    Phase:

    I
    This research study is being done to test the safety of an investigational treatment called LY4066434 when given alone or with other cancer drugs. LY4066434 is an investigational (or experimental) drug, taken orally. It was designed for patients that have abnormalities (also known as DNA mutations) in the KRAS gene that can occur in some types of cancer. LY4066434 is not approved by the U.S. Food and Drug Administration. Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age, 2. Must be able to swallow tablets. 3. Must be able to comply with outpatient treatment, laboratory...

  • A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03947385

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to evaluate the safety profile of IDE196 (an “investigational” drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as: metastatic uveal melanoma, cutaneous melanoma or colorectal cancer or cancers with mutations in genes called GNAQ, GNA11, or PRKC fusion. The study may last for approximately 25 months and your participation will depend on how well you tolerate the study drug and your overall condition during the study. Are you Eligible? (Inclusion Criteria) Do you have a solid tumor(s) that...

Pages